Cardiovascular

Latest News

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

By Kyle Munz
Siddharth M. Patel, MD, MPH

April 24th 2025

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

One's ZIP code can greatly influence care access | image credit: Syda Productions - stock.adobe.com

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

By Kyle Munz
Antoine Keller, MD, FACC, FACS

April 18th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

By Kyle Munz
Jeremy Wigginton, MD

April 8th 2025

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

By Giuliana Grossi
Christian Ruff, MD

April 4th 2025

Heart disease is, and has been, the number 1 cause of death for Americans over the last century | image credit: Thirakun - stock.adobe.com

Digital Solutions Can Transform CVD Care, Prevention

By Kyle Munz

April 2nd 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

Watch Now

Continuing Medical Education

View All

April 25th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases

April 25th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

April 25th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

February 9th 2018

MedPAC Reports Lower Readmission Rates and Reduced Medicare Spending With HRRP

Surabhi Dangi-Garimella, PhD

According to the Medicare Payment Advisory Commission (MedPAC), hospital readmission rates have fallen following implementation of the Hospital Readmissions Reduction Program (HRRP), and HRRP did not have a negative impact on mortality rates.

February 5th 2018

Genetic Testing a Must for Relatives of Cardiomyopathy Patients

Kaitlynn Ely

With 4 in 10 cardiomyopathies having genetic links, there is a need for relatives of patients with cardiomyopathy to be screened in order to prevent early death, according to a recent study published in European Heart Journal.

February 3rd 2018

Catheter Ablation More Effective Than Traditional Therapy in Atrial Fibrillation

Samantha DiGrande

A new study published in the February issue of the New England Journal of Medicine found that patients that received radiofrequency catheter ablation compared with traditional drug therapies for atrial fibrillation (AF) had significantly lower hospitalization and mortality rates.

February 1st 2018

Higher Resting Heart Rate Associated With Adverse CV, Non-CV Events

Jaime Rosenberg

Higher resting heart rate (HR) and increases in HR over time are associated with increased risk of adverse cardiovascular (CV) and non-CV events, such as incident heart failure and all-cause mortality, according to a study published in JAMA Cardiology.

February 1st 2018

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

January 30th 2018

Prime Therapeutics, Boehringer-Ingelheim Reach Outcomes-Based Contract for Jardiance

Mary Caffrey

Empagliflozin (Jardiance) and another SGLT2 inhibitor, canagliflozin (Invokana) have been competing aggressively; both have clinical trial results showing cardiovascular benefits.

January 25th 2018

ODYSSEY Outcomes Results for Sanofi's Praluent to Lead Off ACC Meeting

Mary Caffrey

The annual meeting of the American College of Cardiology (ACC), which runs March 10-12, 2018, in Orlando, Florida, will open with cardiovascular outcomes results for the PCSK9 inhibitor alirocumab (Praluent). The meeting also features updates on anti-inflammatory drugs, the use of SGLT2 inhibitors in heart failure, and how cardiology is shifting to new healthcare delivery models.

January 20th 2018

Study Finds Prior Authorization Mandates for PCSK9 Drugs Raise Questions of Access

Mary Caffrey

Researchers were especially concerned about barriers for patients with familial hypercholesterolemia, whose needs would seem clear cut but who nonetheless faced costly hurdles, such as genetic testing.

January 17th 2018

A Cost-Effectiveness Analysis of Cardiology eConsults for Medicaid Patients

Daren Anderson, MD Victor Villagra, MD Emil N. Coman, PhD Ianita Zlateva, MPH Alex Hutchinson, MBA Jose Villagra, BS J. Nwando Olayiwola, MD, MPH

A randomized trial of eConsults for cardiology referrals from primary care resulted in significant reductions in total cost of care compared with traditional face-to-face consultations.

January 13th 2018

Dr Amar Bhakta on Changing the Approach to Treating Heart Failure

Reimbursement structures and population demographics change the way hospitals approach heart failure, explained Amar Bhakta, MD, of Rush University Medical Center.

January 12th 2018

Chronic Inflammation, Dyslipidemia Puts Children, Teens With HIV at Higher CV Risk, Study Finds

Mary Caffrey

The same mechanisms that cause those with long-term HIV infection to suffer higher rates of heart attacks or strokes put children born with disease at early risk of cardiovascular disease, according to a new study.

January 10th 2018

CMS Unveils New Voluntary Bundled Payment Model

Mary Caffrey

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

January 10th 2018

CMS Unveils New Voluntary Bundled Payment Model

Mary Caffrey

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

January 3rd 2018

New Cholesterol Test More Accurate Than Old Test That Requires Fasting

Laura Joszt, MA

A newer method for calculating low-density lipoprotein (LDL) cholesterol is more accurate than the older method that required people fast before blood was drawn.

December 26th 2017

Perspectives of a Lipidologist: LDL Cholesterol Testing, PCSK9 Inhibitors

Mary Caffrey

December 21st 2017

Dr Todd Hobbs Discusses Identifying and Removing Barriers to Care for Obesity

Although patients and physicians both recognize the need to discuss obesity, the lack of resources, time, and expertise often prevents physicians for offering care and patients from asking for it, explained Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer.

December 21st 2017

Conference Stories That Captivated AJMC® Readers in 2017

Samantha DiGrande

In 2017, The American Journal of Managed Care® (AJMC®) covered conferences on a range of topics: oncology, diabetes, managed care, and much more. however, the most-read coverage from conferences that AJMC® attended mostly focused on cardiology trial results, particularly the cardiovascular results of diabetes medications.

December 21st 2017

Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity

Trial results have shown that alirocumab (Praluent) is safe and effective across patient populations, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.

December 19th 2017

The CVD-Real Trial: What Can Real-World Evidence Tell Us About Primary Prevention?

Mary Caffrey

An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.

December 19th 2017

Improved Recommendations of Deintensification in Clinical Guidelines Is Needed

Laura Joszt, MA

Currently, clinical guidelines offer little guidance on deintensifying care, which is critical for balancing overuse and underuse of services.

December 18th 2017

As Trials Report Cardiovascular Outcomes Data, What About Microvascular Results?

Andrew Smith

Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.

December 17th 2017

Dr Amar Bhakta Explains a New Pathway to Prevent Heart Failure Readmissions

A new pathway uses a multidisciplinary team to help reduce 30-day heart failure readmissions, explained Amar Bhakta, MD, of Rush University Medical Center.

December 14th 2017

For Those With Diabetes and CV Risk, Personalized Care Matters

Robert A. Gabbay, MD, PhD, FACP

From the Editor in Chief

December 13th 2017

MGH: Centralized population health coordinators help improve care for patients with chronic disease

December 8th 2017

AJMC® in the Press, December 8, 2017

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

December 5th 2017

Dr Todd Hobbs Discusses the Advantages of Semaglutide in Type 2 Diabetes

On December 5, 2017, FDA approved Novo Nordisk’s semaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer, spoke with The American Journal of Managed Care® just ahead of FDA’s action.

December 5th 2017

Targeting Lipids May Improve Outcomes of Abdominal Aortic Aneurysm

Laura Joszt, MA

Abdominal aortic aneurysm is a cardiovascular disease for which 45,000 operations are performed yearly in the United States, but a new study found that targeting lipids may improve long-term outcomes.

December 1st 2017

AJMC® in the Press, December 1, 2017

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

December 1st 2017

Dr Eliot A. Brinton: Perspectives on PCSK9 Inhibitors

Results from the FOURIER trial have provided convincing data that there is no downside to aggressively lowering cholesterol with PCSK9 inhibitors, and studies have shown there are cardiovascular benefits associated with Repatha, but reimbursement remains challenging, said Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.

November 29th 2017

Any Physical Activity Lowers CVD Risk for Elderly, Study Finds

Jaime Rosenberg

Physical activity, even of a low-intensity, reduces the risk of cardiovascular disease in older adults, according to a study published in The European Journal of Preventive Cardiology. Although the authors found similar associations for individuals under age 55 and individuals aged 55-65, the results were not statistically significant.

...

9 10 11 12 13 14 15 16 17

...

23 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions